Siegfried Holding AG Share Price London S.E.

Equities

0QQO

CH0014284498

Pharmaceuticals

Real-time Estimate Cboe Europe 06:37:01 04/06/2024 pm IST 5-day change 1st Jan Change
873 CHF -1.02% Intraday chart for Siegfried Holding AG +0.34% +2.48%

Financials

Sales 2024 * 1.3B 1.46B 121B Sales 2025 * 1.42B 1.59B 132B Capitalization 3.81B 4.27B 356B
Net income 2024 * 148M 166M 13.83B Net income 2025 * 172M 192M 16.07B EV / Sales 2024 * 3.2 x
Net Debt 2024 * 351M 392M 32.77B Net Debt 2025 * 313M 351M 29.28B EV / Sales 2025 * 2.91 x
P/E ratio 2024 *
25.7 x
P/E ratio 2025 *
22.1 x
Employees 3,945
Yield 2024 *
0.43%
Yield 2025 *
0.46%
Free-Float 87.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.02%
1 week+0.34%
Current month-1.89%
1 month+1.38%
3 months-2.54%
6 months+12.72%
Current year+2.48%
More quotes
1 week
873.00
Extreme 873
903.00
1 month
844.00
Extreme 844
903.00
Current year
828.00
Extreme 828
947.50
1 year
657.50
Extreme 657.5
947.50
3 years
566.50
Extreme 566.5
947.50
5 years
316.50
Extreme 316.5
947.50
10 years
137.49
Extreme 137.4855
947.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 01/17/01
Chief Tech/Sci/R&D Officer 56 01/19/01
Corporate Officer/Principal - 01/14/01
Members of the board TitleAgeSince
Director/Board Member 55 01/16/01
Director/Board Member 63 01/14/01
Chairman 61 01/10/01
More insiders
Date Price Change Volume
30/24/30 882 +26.36% 25
03/24/03 886.7 -1.36% 106
31/24/31 899 +2.16% 235
30/24/30 880 +0.46% 205
29/24/29 876 -0.34% 175

Delayed Quote London S.E., April 30, 2024 at 09:10 pm IST

More quotes
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
889 CHF
Average target price
1,016 CHF
Spread / Average Target
+14.27%
Consensus